搜索结果
疾病ID:TCMBANKDI018707
疾病名:Marfan Syndrome
MeSH_Name:Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Cardiovascular Diseases
HPO_Name:-
UMLS_Name:Disease or Syndrome
DO_Name:disease of anatomical entity
疾病类型:disease
DisGeNET_Link:C0024796
MeSH_Link:C16; C17; C05; C14
HPO_Link:-
UMLS_Link:T047
DO_Link:DOID:7
HERB_ID:-
疾病对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
疾病对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
疾病对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE000973 | EGF | HOMG4; URG | epidermal growth factor |
| TCMBANKGE001180 | SMAD3 | HSPC193; HsT17436; JV15-2; LDS1C; LDS3; MADH3 | SMAD family member 3 |
| TCMBANKGE000857 | AHSA1 | AHA1; C14orf3; hAha1; p38 | activator of HSP90 ATPase activity 1 |
| TCMBANKGE013782 | LTBP2 | C14orf141; GLC3D; LTBP3; MSPKA; MSTP031; WMS3 | latent transforming growth factor beta binding protein 2 |
| TCMBANKGE000944 | NOTCH3 | CADASIL; CADASIL1; CASIL; IMF2; LMNS | notch receptor 3 |
| TCMBANKGE000192 | CDH5 | 7B4; CD144 | cadherin 5 |
| TCMBANKGE006975 | THBS1 | THBS; THBS-1; TSP; TSP-1; TSP1 | thrombospondin 1 |
| TCMBANKGE001104 | TGFB2 | G-TSF; LDS4; TGF-beta2 | transforming growth factor beta 2 |
| TCMBANKGE003689 | MFAP1 | AMP | microfibril associated protein 1 |
| TCMBANKGE006849 | FBN3 | - | fibrillin 3 |
| TCMBANKGE010304 | ADAMTS1 | C3-C5; METH1 | ADAM metallopeptidase with thrombospondin type 1 motif 1 |
| TCMBANKGE013767 | CBSL | CBS | cystathionine beta-synthase like |
| TCMBANKGE002700 | SLC35A1 | CDG2F; CMPST; CST; hCST | solute carrier family 35 member A1 |
| TCMBANKGE000173 | BRAF | B-RAF1; B-raf; BRAF1; NS7; RAFB1 | B-Raf proto-oncogene, serine/threonine kinase |
| TCMBANKGE000162 | MMP13 | CLG3; MANDP1; MDST; MMP-13 | matrix metallopeptidase 13 |
| TCMBANKGE013010 | COX2 | COII; MTCO2 | cytochrome c oxidase subunit II |
| TCMBANKGE007174 | FADS3 | CYB5RP; LLCDL3 | fatty acid desaturase 3 |
| TCMBANKGE001076 | SOD2 | GClnc1; IPO-B; IPOB; MNSOD; MVCD6; Mn-SOD | superoxide dismutase 2 |
| TCMBANKGE000818 | ROS1 | MCF3; ROS; c-ros-1 | ROS proto-oncogene 1, receptor tyrosine kinase |
| TCMBANKGE009975 | LAMC2 | B2T; BM600; CSF; EBR2; EBR2A; LAMB2T; LAMNB2 | laminin subunit gamma 2 |
| TCMBANKGE002175 | COL3A1 | EDS4A; EDSVASC; PMGEDSV | collagen type III alpha 1 chain |
| TCMBANKGE004039 | SIGLEC7 | AIRM1; CD328; CDw328; D-siglec; QA79; SIGLEC-7; SIGLEC19P; SIGLECP2; p75; p75/AIRM1 | sialic acid binding Ig like lectin 7 |
| TCMBANKGE004283 | FBN2 | CCA; DA9; EOMD | fibrillin 2 |
| TCMBANKGE001074 | ATM | AT1; ATA; ATC; ATD; ATDC; ATE; TEL1; TELO1 | ATM serine/threonine kinase |
| TCMBANKGE000205 | NOS2 | HEP-NOS; INOS; NOS; NOS2A | nitric oxide synthase 2 |
| TCMBANKGE013422 | CD109 | CPAMD7; p180; r150 | CD109 molecule |
| TCMBANKGE013655 | SLC33A1 | ACATN; AT-1; AT1; CCHLND; SPG42 | solute carrier family 33 member 1 |
| TCMBANKGE000568 | MET | AUTS9; DFNB97; HGFR; RCCP2; c-Met | MET proto-oncogene, receptor tyrosine kinase |
| TCMBANKGE000298 | SOD1 | ALS; ALS1; HEL-S-44; IPOA; SOD; STAHP; hSod1; homodimer | superoxide dismutase 1 |
| TCMBANKGE001203 | MAPK1 | ERK; ERK-2; ERK2; ERT1; MAPK2; P42MAPK; PRKM1; PRKM2; p38; p40; p41; p41mapk; p42-MAPK | mitogen-activated protein kinase 1 |
| TCMBANKGE011264 | FBLN5 | ADCL2; ARCL1A; ARMD3; DANCE; EVEC; FIBL-5; HNARMD; UP50 | fibulin 5 |
| TCMBANKGE000282 | ELN | ADCL1; SVAS; WBS; WS | elastin |
| TCMBANKGE001844 | TGFBR3 | BGCAN; betaglycan | transforming growth factor beta receptor 3 |
| TCMBANKGE001179 | SMAD2 | JV18; JV18-1; MADH2; MADR2; hMAD-2; hSMAD2 | SMAD family member 2 |
| TCMBANKGE000321 | NOX4 | KOX; KOX-1; RENOX | NADPH oxidase 4 |
| TCMBANKGE012010 | LAMC1 | LAMB2 | laminin subunit gamma 1 |
| TCMBANKGE009359 | VCAN | CSPG2; ERVR; GHAP; PG-M; WGN; WGN1 | versican |
| TCMBANKGE000611 | CSF2 | CSF; GMCSF | colony stimulating factor 2 |
| TCMBANKGE001107 | NOS3 | ECNOS; eNOS | nitric oxide synthase 3 |
| TCMBANKGE007141 | MTHFR | - | methylenetetrahydrofolate reductase |
| TCMBANKGE012039 | ACSM3 | SA; SAH | acyl-CoA synthetase medium chain family member 3 |
| TCMBANKGE001037 | MMP2 | CLG4; CLG4A; MMP-2; MMP-II; MONA; TBE-1 | matrix metallopeptidase 2 |
| TCMBANKGE000627 | BGLAP | BGP; OC; OCN | bone gamma-carboxyglutamate protein |
| TCMBANKGE001153 | EPHB2 | BDPLT22; CAPB; DRT; EK5; EPHT3; ERK; Hek5; PCBC; Tyro5 | EPH receptor B2 |
| TCMBANKGE000160 | COL2A1 | ANFH; AOM; COL11A3; SEDC; STL1 | collagen type II alpha 1 chain |
| TCMBANKGE008178 | SULT1E1 | EST; EST-1; ST1E1; STE | sulfotransferase family 1E member 1 |
| TCMBANKGE001544 | GAL3ST1 | CST | galactose-3-O-sulfotransferase 1 |
| TCMBANKGE000687 | POLDIP2 | PDIP38; POLD4; p38 | DNA polymerase delta interacting protein 2 |
| TCMBANKGE013948 | TGFB3 | ARVD; ARVD1; LDS5; RNHF; TGF-beta3 | transforming growth factor beta 3 |
| TCMBANKGE001405 | SPRTN | C1orf124; DVC1; PRO4323; spartan | SprT-like N-terminal domain |
| TCMBANKGE001202 | MAPK14 | CSBP; CSBP1; CSBP2; CSPB1; EXIP; Mxi2; PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA | mitogen-activated protein kinase 14 |
| TCMBANKGE001182 | SIRT1 | SIR2; SIR2L1; SIR2alpha | sirtuin 1 |
| TCMBANKGE004724 | FBN1 | ACMICD; ECTOL1; FBN; GPHYSD2; MASS; MFLS; MFS1; OCTD; SGS; SSKS; WMS; WMS2 | fibrillin 1 |
| TCMBANKGE009586 | CNN1 | HEL-S-14; SMCC; Sm-Calp | calponin 1 |
| TCMBANKGE001073 | PTGS2 | COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2 | prostaglandin-endoperoxide synthase 2 |
| TCMBANKGE000224 | AGT | ANHU; SERPINA8; hFLT1 | angiotensinogen |
| TCMBANKGE003565 | TGFBR1 | AAT5; ACVRLK4; ALK-5; ALK5; ESS1; LDS1; LDS1A; LDS2A; MSSE; SKR4; TBR-i; TBRI; TGFR-1; tbetaR-I | transforming growth factor beta receptor 1 |
| TCMBANKGE001113 | ACTA2 | ACTSA | actin alpha 2, smooth muscle |
| TCMBANKGE001030 | NOTCH1 | AOS5; AOVD1; TAN1; hN1 | notch receptor 1 |
| TCMBANKGE010402 | NF1 | NFNS; VRNF; WSS | neurofibromin 1 |
| TCMBANKGE000273 | LOX | AAT10 | lysyl oxidase |
| TCMBANKGE000569 | CD34 | - | CD34 molecule |
| TCMBANKGE001176 | CAT | - | catalase |
| TCMBANKGE001051 | MAP2K7 | JNKK2; MAPKK7; MEK; MEK 7; MKK7; PRKMK7; SAPKK-4; SAPKK4 | mitogen-activated protein kinase kinase 7 |
| TCMBANKGE005666 | DCN | CSCD; DSPG2; PG40; PGII; PGS2; SLRR1B | decorin |
| TCMBANKGE014962 | COX8A | COX; COX8; COX8-2; COX8L; VIII; VIII-L | cytochrome c oxidase subunit 8A |
| TCMBANKGE001599 | SLC3A1 | ATR1; CSNU1; D2H; NBAT; RBAT | solute carrier family 3 member 1 |
| TCMBANKGE001065 | KLF4 | EZF; GKLF | Kruppel like factor 4 |
| TCMBANKGE008481 | VWF | F8VWF; VWD | von Willebrand factor |
| TCMBANKGE014918 | DCBLD2 | CLCP1; ESDN | discoidin, CUB and LCCL domain containing 2 |
| TCMBANKGE008490 | RNF19A | RNF19 | ring finger protein 19A, RBR E3 ubiquitin protein ligase |
| TCMBANKGE000109 | ACTB | BRWS1; PS1TP5BP1 | actin beta |
| TCMBANKGE010690 | PLXNA2 | OCT; PLXN2 | plexin A2 |
| TCMBANKGE000445 | CD44 | CDW44; CSPG8; ECMR-III; HCELL; HUTCH-I; IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1 | CD44 molecule (Indian blood group) |
| TCMBANKGE014567 | SLC12A3 | NCC; NCCT; TSC | solute carrier family 12 member 3 |
| TCMBANKGE000522 | AGTR1 | AG2S; AGTR1B; AT1; AT1AR; AT1B; AT1BR; AT1R; AT2R1; HAT1R | angiotensin II receptor type 1 |
| TCMBANKGE000856 | CRK | CRKII; p38 | CRK proto-oncogene, adaptor protein |
| TCMBANKGE010969 | LRP1 | A2MR; APOER; APR; CD91; IGFBP-3R; IGFBP3R; IGFBP3R1; KPA; LRP; LRP1A; TGFBR5 | LDL receptor related protein 1 |
| TCMBANKGE000302 | KCNQ1 | ATFB1; ATFB3; JLNS1; KCNA8; KCNA9; KVLQT1; Kv1.9; Kv7.1; LQT; LQT1; RWS; SQT2; WRS | potassium voltage-gated channel subfamily Q member 1 |
| TCMBANKGE007230 | FXN | CyaY; FA; FARR; FRDA; X25 | frataxin |
| TCMBANKGE000689 | GRAP2 | GADS; GRAP-2; GRB2L; GRBLG; GRID; GRPL; GrbX; Grf40; Mona; P38 | GRB2 related adaptor protein 2 |
| TCMBANKGE008164 | TGFBI | BIGH3; CDB1; CDG2; CDGG1; CSD; CSD1; CSD2; CSD3; EBMD; LCD1 | transforming growth factor beta induced |
| TCMBANKGE000214 | SCD | FADS5; MSTP008; SCD1; SCDOS; hSCD1 | stearoyl-CoA desaturase |
| TCMBANKGE006724 | REN | HNFJ2 | renin |
| TCMBANKGE000646 | DECR1 | DECR; NADPH; SDR18C1 | 2,4-dienoyl-CoA reductase 1 |
| TCMBANKGE001185 | PPARG | CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma | peroxisome proliferator activated receptor gamma |
| TCMBANKGE008225 | COL1A2 | EDSARTH2; EDSCV; OI4 | collagen type I alpha 2 chain |
| TCMBANKGE014176 | ANGPT2 | AGPT2; ANG2 | angiopoietin 2 |
| TCMBANKGE013106 | TIMP3 | HSMRK222; K222; K222TA2; SFD | TIMP metallopeptidase inhibitor 3 |
| TCMBANKGE001201 | MAPK3 | ERK-1; ERK1; ERT2; HS44KDAP; HUMKER1A; P44ERK1; P44MAPK; PRKM3; p44-ERK1; p44-MAPK | mitogen-activated protein kinase 3 |
| TCMBANKGE000749 | ALOX5 | 5-LO; 5-LOX; 5LPG; LOG5 | arachidonate 5-lipoxygenase |
| TCMBANKGE000846 | MMP14 | MMP-14; MMP-X1; MT-MMP; MT-MMP 1; MT1-MMP; MT1MMP; MTMMP1; WNCHRS | matrix metallopeptidase 14 |
| TCMBANKGE007248 | PGR-AS1 | AT1; AT2; AT3 | PGR antisense RNA 1 |
| TCMBANKGE001122 | AXIN2 | AXIL; ODCRCS | axin 2 |
| TCMBANKGE012899 | ADAMTSL4 | ADAMTSL-4; ECTOL2; TSRC1 | ADAMTS like 4 |
| TCMBANKGE011878 | GPR162 | A-2; GRCA | G protein-coupled receptor 162 |
| TCMBANKGE000696 | PKD1 | PBP; PC1; Pc-1; TRPP1 | polycystin 1, transient receptor potential channel interacting |
| TCMBANKGE008040 | CLDN6 | - | claudin 6 |
| TCMBANKGE013076 | CBS | CBSL; HIP4 | cystathionine beta-synthase |
| TCMBANKGE000688 | AIMP2 | HLD17; JTV-1; JTV1; P38 | aminoacyl tRNA synthetase complex interacting multifunctional protein 2 |
| TCMBANKGE004203 | TGFBR2 | AAT3; FAA3; LDS1B; LDS2; LDS2B; MFS2; RIIC; TAAD2; TBR-ii; TBRII; TGFR-2; TGFbeta-RII | transforming growth factor beta receptor 2 |
| TCMBANKGE000389 | MMP3 | CHDS6; MMP-3; SL-1; STMY; STMY1; STR1 | matrix metallopeptidase 3 |
| TCMBANKGE000012 | TAGLN | SM22; SM22-alpha; SMCC; TAGLN1; WS3-10 | transgelin |
| TCMBANKGE000764 | TRPV1 | VR1 | transient receptor potential cation channel subfamily V member 1 |
| TCMBANKGE007151 | TIMP2 | CSC-21K; DDC8 | TIMP metallopeptidase inhibitor 2 |
| TCMBANKGE000712 | COL1A1 | CAFYD; EDSARTH1; EDSC; OI1; OI2; OI3; OI4 | collagen type I alpha 1 chain |
滇IICP备16009434号-1 |
Dai SX Lab